Home » Newsletters » BioWorld

BioWorld

Aug. 17, 2009

View Archived Issues

Split Panel Vote Takes Shine off Denosumab: Is PMO Only So-So?

As the dust settled following Thursday's messy panel vote, Amgen Inc.'s much-touted bone drug looked a bit worse for wear. (BioWorld Today) Read More

Clinical Data Driving Biotech's Rebound So Far, BIO Reports

New Evidence for Autoimmunity Connection to Psych Disorders

NewCo News: Treventis has Multiple Targets as It Focuses on Alzheimer's

AGI Loses Axcan as Partner on GERD Drug Omeprazole

Other News To Note

Clinic Roundup

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 17, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.